The FDA has approved the drug Kalydeco to be used towards the treatment of a rare form of cystic fibrosis in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator gene.
Read the full announcement here

Posted on:  February 1, 2012